An Bloomberg Opinion article by Lisa Jarvis highlights the economic challenges of paying for new cell and gene therapies. Given the cost of development and, more importantly, the cost of goods, these therapies are necessarily expensive, and will be for a long time. New financial engineering solutions, which she writes about, are hardly going to solve the problem – someone will pay the cost. And government intervention is a long way off.
read full article ›In case you missed it, Real Endpoints Julia Murphy provided some great intel on strategies to equip pharma #FieldSalesTeam to drive meaningful #PatientOutcomes in this webinar. You can catch the replay here: https://lnkd.in/eD5SwsSn Thanks to Phil, Inc. for including us in the discussion.
read full article ›Real Endpoints Rob O'Brien met with payer and pharmacy peeps last week to get the skinny on management of weight loss meds (among other topics). Given their budget busting potential AND the demonstrated efficacy of these products, this is an area to watch.
read full article ›In a presentation designed to make people stop and think, Jeff Berkowitz outlined how a sophisticated understanding of market access is key to commercial success for biotechs. "You can do great science and great medicine - and still lose your shirt," he told the audience. Far from being a "gloomy gus," he also gave concrete advice about what to do in an environment where payers have more leverage. Key actions: ensure market access is appropriately resourced and that CEOs and leadership teams are accountable for it.
read full article ›Shameless promotion of colleagues. Rob O'Brien will be moderating a panel on the payer perspective around industry disruption. No shortage of topics on that front to bring up, that's for sure!
read full article ›News in recent months of strategic shifts or closures at #PDT leaders highlights how tough the prescription digital therapeutics business. One of the primary reasons things are tough? There isn't a straightforward path to reimbursement by payers. As such, the subcommittee hearing scheduled for Sept. 19 is a very important step forward for #PDT businesses. It's an even bigger step forward for patients who may benefit from these new digital modalities.
read full article ›The @Real Endpoints team had so much fun participating in the latest Insight Exchange with Alex Guth and Matthew Mancuso of L.E.K. to highlight learnings from our inaugural gene therapy commercial meeting. Tune in to hear Roger Longman and Ellen Licking opine (because, you know, that soooo rarely happens. 😉)
read full article ›As PBM reform heats up on Capital Hill, this story is sure to make waves. Not only are there juicy quotes about how intermediaries are making money at the expense of consumers, but it highlights the perverse incentives that have been created as insurers have bought up PBMs. As one industry watcher told us, "this is another nail the PBM coffin, but it's clearly going to take a long time for the coffin to be finished."
read full article ›Today's must-read story post the announcement of the first 10 drugs to face drug price negotiation is from the team at STAT. It is a reminder that when it comes to what to do about rising healthcare costs, hospitals and doctors aren't necessarily in favor of price caps either.
read full article ›Brian Reid lays out another essential daily dozen #IRA related news stories in today's newsletter. If you are interested in drug policy and reimbursement or how to communicate product value, do yourself a favor and subscribe to Cost Curve.
read full article ›